OptiNose

Company Profile

OptiNose had its IPO on 2017-10-13 under the ticker symbol OPTN.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. OptiNose has a staff strength of 141 employees.

Stock update

Shares of OptiNose opened at $1.24 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.22 - $1.26, and closed at $1.25.

This is a +1.63% increase from the previous day's closing price.

A total volume of 121,628 shares were traded at the close of the day’s session.

In the last one week, shares of OptiNose have slipped by -1.57%.

OptiNose's Key Ratios

OptiNose has a market cap of $138.03 million, indicating a price to book ratio of 24.2559 and a price to sales ratio of 2.4666.

In the last 12-months OptiNose’s revenue was $72.23 million with a gross profit of $67.01 million and an EBITDA of $-37243000. The EBITDA ratio measures OptiNose's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, OptiNose’s operating margin was -52.19% while its return on assets stood at -20.59% with a return of equity of -1050.5%.

In Q2, OptiNose’s quarterly earnings growth was a positive 0% while revenue growth was a negative 5.5%.

OptiNose’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.49 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into OptiNose’s profitability.

OptiNose stock is trading at a EV to sales ratio of 3.3414 and a EV to EBITDA ratio of -4.4618. Its price to sales ratio in the trailing 12-months stood at 2.4666.

OptiNose stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$106.07 million

Total Liabilities

$164.30 million

Operating Cash Flow

$-79000.00

Capital Expenditure

$79000

Dividend Payout Ratio

0%

OptiNose ended 2024 with $106.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $106.07 million while shareholder equity stood at $-69660000.00.

OptiNose ended 2024 with $0 in deferred long-term liabilities, $164.30 million in other current liabilities, 112000.00 in common stock, $-701114000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $71.31 million and cash and short-term investments were $71.31 million. The company’s total short-term debt was $130,794,000 while long-term debt stood at $0.

OptiNose’s total current assets stands at $103.61 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $22.13 million compared to accounts payable of $6.48 million and inventory worth $7.73 million.

In 2024, OptiNose's operating cash flow was $-79000.00 while its capital expenditure stood at $79000.

Comparatively, OptiNose paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.25

52-Week High

$3.976

52-Week Low

$0.9

Analyst Target Price

$3

OptiNose stock is currently trading at $1.25 per share. It touched a 52-week high of $3.976 and a 52-week low of $3.976. Analysts tracking the stock have a 12-month average target price of $3.

Its 50-day moving average was $1.18 and 200-day moving average was $1.56 The short ratio stood at 8.6 indicating a short percent outstanding of 0%.

Around 739.7% of the company’s stock are held by insiders while 7840.5% are held by institutions.